JBM Healthcare sees strong interim revenue and profit growth

JBM Healthcare Limited announced a 7.7% year-on-year increase in total revenue to HK$429.6 million for the six months ended September 30, 2025, compared to HK$398.9 million in the previous interim period. Gross profit surged by 23.2% to HK$253.6 million, with profit attributable to equity shareholders rising 20.0% to HK$115.0 million. This growth was largely propelled by strong sales in branded medicines and proprietary Chinese medicines, particularly Ho Chai Kung and Po Chai Pills.

The branded medicines segment grew by 15.5% to HK$150.9 million, while proprietary Chinese medicines saw a 7.6% increase to HK$236.5 million. The health and wellness products segment experienced a 13.2% decline to HK$42.2 million, primarily due to product rationalization and softer consumer demand, partially offset by stable growth of the Oncotype DX Breast Cancer Recurrence Score Test. Adjusted EBITDA climbed 21.7% to HK$175.3 million.

Geographically, Hong Kong remained the primary revenue contributor, accounting for 86% of total revenue with an increase of HK$102.8 million. The company also expanded its e-commerce network, with proprietary brands performing strongly across major online platforms in the Chinese mainland, despite a decline in overall Chinese mainland revenue due to product rationalization.